World Health Organization Raises Warning Over Critical Scarcity of Weight-Loss Jabs
Under one in 10 patients that would benefit from GLP-1 drugs such as Wegovy have access to them, caution the World Health Organization as it issues its inaugural advice on the therapies.
Given in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for more widespread and fairer availability to this class of drugs.
Based on projections, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"Our new guidelines recognises that obesity is a chronic disease that can be addressed with holistic and continuous care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant barriers to broad availability to the treatments that can assist patients in reducing considerable body mass, says the organization.
GLP-1 Therapy Scarcity
Despite the current best projected scenario, the manufacturing of these medications might only reach approximately 100 million people – less than 10% of eligible patients, according to the WHO.
The recommendation encourages countries and companies to expand access, via approaches including licensing agreements.
Exclusive production rights on a key compound – the core ingredient of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026.
The Way Weight-Loss Jabs Operate
These medications imitate a body's own hormone to slow digestion, reduce hunger and boost feelings of fullness so people eat less.
Individuals usually begin shedding pounds after several weeks of commencing the once-weekly jabs.
Studies indicates people may regain a significant portion after a year of discontinuing the treatment, as their typical food cravings come back.
To be above a healthy weight raises your chance for contracting medical conditions, such as diabetes, cardiovascular issues, brain attack, and some cancers.
Obesity concerns people in every country and was associated with millions of fatalities worldwide in 2024, according to the health agency.